TJ Cradick

TJ Cradick is the Chief Scientific Officer (CSO) at Excision BioTherapeutics, a clinical-stage biotech company that is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients. With over 20 years of experience in nucleases, genome editing, and gene therapy, TJ leads Excision’s scientific vision and strategy, oversees the research and development of its pipeline projects, and manages collaborations with academic and industry partners.

TJ was formerly the Head of Genome Editing at CRISPR Therapeutics. As the 2nd U.S. CRISPR Tx employee, he had many responsibilities through the company’s progression to a clinical stage company with >300 employees.  The Casgevy program was started at Georgia Tech, where TJ was faculty and Director of the Protein Engineering Facility, researching different CRISPR nuclease orthologs, Zinc Finger Nucleases (ZFNs) and TALENs, plus bioinformatics and assays for on- & off-target events.  TJ’s gene editing experience started at Sangamo Biosciences, joining the zinc finger design and selection group in 2000,

TJ is a recognized leader and innovator in the field of CRISPR/Cas9 technology, having published influential papers on its applications, mechanisms, and specificity.  He is also a Scientific Advisory Board Member at CRISP-HR Therapeutics, Inc. and at Catalytic Data Science. TJ is passionate about advancing the science and practice of gene editing to address unmet medical needs and transform the lives of patients.